We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alcon Stock Gains Following the Launch of Clareon TruPlus at ASCRS
Read MoreHide Full Article
Key Takeaways
ALC launched Clareon TruPlus IOL in the US at ASCRS, expanding its cataract surgery portfolio.
TruPlus uses Opti-Balance Technology to extend focus depth while preserving strong distance image quality.
ALC benefits from a growing global IOL market projected to reach $9.52B by 2034 with rising cataract demand.
Alcon (ALC - Free Report) recently announced the U.S. launch of Clareon TruPlus, its newly enhanced monofocal and toric intraocular lens (IOL). It was introduced at the American Society of Cataract and Refractive Surgery (“ASCRS”) annual meeting in Washington, D.C., with a broader rollout to additional markets planned later this year.
TruPlus expands Alcon’s leading Clareon portfolio by offering surgeons an enhanced IOL design IOL that improves depth of focus without compromising high-quality distance vision.
ALC Stock’s Likely Trend Following the News
Since the announcement, ALC shares have surged 0.05%, closing yesterday’s session at $74.67.
With more than 175 million IOLs implanted globally, Alcon is a leader in cataract surgery. TruPlus joins Alcon’s broad portfolio of Clareon IOLs that includes the top monofocal lens, Vivity — a leading extended depth of focus lens and PanOptix and PanOptix Pro — the most widely used trifocal lenses in the world. We expect the news to further boost ALC stock price in the upcoming days.
Alcon has a market capitalization of $36.81 billion at present. The company’s earnings yield of 4.6% compares favorably to the industry’s negative 1.9% yield.
Significance of ALC’s TruPlus
TruPlus leverages proprietary Opti-Balance Technology at the center of the lens to modestly extend depth of focus. This innovative design enhances light energy distribution, increasing depth of focus while maintaining exceptional distance image quality and a broad refractive landing zone.
Based on bench data, TruPlus demonstrates several differentiating features compared to Clareon Monofocal and the leading competitor intraocular lenses (IOLs). It shows a 3.5-letter improvement in simulated visual acuity at -1.5 diopters (66 cm) relative to Clareon Monofocal. TruPlus provides higher distance image quality than TECNIS Eyhance across a variety of pupil sizes and lighting conditions, while also exceeding the ISO upper requirement for distance image quality. It also exhibits a lower glare and halo profile compared to TECNIS Eyhance.
Image Source: Zacks Investment Research
Industry Prospects Favor ALC
Based on a report by Fortune Business Insights, the global IOL market size was valued at $5.14 billion in 2025 and is projected to grow from $5.49 billion in 2026 to $9.52 billion by 2034, at a CAGR of 7.13% during the period. The increasing prevalence of cataracts has surged the demand for these procedures, coupled with significantly advanced product launches, collectively contributing to market growth.
Another Product Launch by ALC
Alcon recently launched TOTAL30 Multifocal for Astigmatism in the United States, the world’s only multifocal toric contact lens featuring Water Gradient Technology. The lenses combine a unique material with advanced optical design to deliver strong visual performance for astigmatic presbyopes at a competitive price.
ALC Stock Price Performance
Over the past year, Alcon stock has plunged 17% compared with the industry’s 1.1% decline.
BrightSpring Health Services shares have soared 165.4% over the past year. Estimates for the company’s 2026 EPS have jumped 15% to $1.61 in the past 60 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%.
Globus Medical shares have risen 29.1% over the past year. Estimates for the company’s 2026 EPS have increased 14.7% to $4.46 in the past 60 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%.
Estimates for IDEXX Laboratories’ 2026 EPS have increased 0.6% in the past 60 days. Shares of the company have surged 60.1% over the past year compared with the industry’s 8.4% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.1%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Alcon Stock Gains Following the Launch of Clareon TruPlus at ASCRS
Key Takeaways
Alcon (ALC - Free Report) recently announced the U.S. launch of Clareon TruPlus, its newly enhanced monofocal and toric intraocular lens (IOL). It was introduced at the American Society of Cataract and Refractive Surgery (“ASCRS”) annual meeting in Washington, D.C., with a broader rollout to additional markets planned later this year.
TruPlus expands Alcon’s leading Clareon portfolio by offering surgeons an enhanced IOL design IOL that improves depth of focus without compromising high-quality distance vision.
ALC Stock’s Likely Trend Following the News
Since the announcement, ALC shares have surged 0.05%, closing yesterday’s session at $74.67.
With more than 175 million IOLs implanted globally, Alcon is a leader in cataract surgery. TruPlus joins Alcon’s broad portfolio of Clareon IOLs that includes the top monofocal lens, Vivity — a leading extended depth of focus lens and PanOptix and PanOptix Pro — the most widely used trifocal lenses in the world. We expect the news to further boost ALC stock price in the upcoming days.
Alcon has a market capitalization of $36.81 billion at present. The company’s earnings yield of 4.6% compares favorably to the industry’s negative 1.9% yield.
Significance of ALC’s TruPlus
TruPlus leverages proprietary Opti-Balance Technology at the center of the lens to modestly extend depth of focus. This innovative design enhances light energy distribution, increasing depth of focus while maintaining exceptional distance image quality and a broad refractive landing zone.
Based on bench data, TruPlus demonstrates several differentiating features compared to Clareon Monofocal and the leading competitor intraocular lenses (IOLs). It shows a 3.5-letter improvement in simulated visual acuity at -1.5 diopters (66 cm) relative to Clareon Monofocal. TruPlus provides higher distance image quality than TECNIS Eyhance across a variety of pupil sizes and lighting conditions, while also exceeding the ISO upper requirement for distance image quality. It also exhibits a lower glare and halo profile compared to TECNIS Eyhance.
Image Source: Zacks Investment Research
Industry Prospects Favor ALC
Based on a report by Fortune Business Insights, the global IOL market size was valued at $5.14 billion in 2025 and is projected to grow from $5.49 billion in 2026 to $9.52 billion by 2034, at a CAGR of 7.13% during the period. The increasing prevalence of cataracts has surged the demand for these procedures, coupled with significantly advanced product launches, collectively contributing to market growth.
Another Product Launch by ALC
Alcon recently launched TOTAL30 Multifocal for Astigmatism in the United States, the world’s only multifocal toric contact lens featuring Water Gradient Technology. The lenses combine a unique material with advanced optical design to deliver strong visual performance for astigmatic presbyopes at a competitive price.
ALC Stock Price Performance
Over the past year, Alcon stock has plunged 17% compared with the industry’s 1.1% decline.
ALC’s Zacks Rank and Other Key Picks
Alcon currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Globus Medical (GMED - Free Report) and IDEXX Laboratories (IDXX - Free Report) . While BTSG and GMED sport a Zacks Rank #1 (Strong Buy) each, IDXX carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring Health Services shares have soared 165.4% over the past year. Estimates for the company’s 2026 EPS have jumped 15% to $1.61 in the past 60 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%.
Globus Medical shares have risen 29.1% over the past year. Estimates for the company’s 2026 EPS have increased 14.7% to $4.46 in the past 60 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%.
Estimates for IDEXX Laboratories’ 2026 EPS have increased 0.6% in the past 60 days. Shares of the company have surged 60.1% over the past year compared with the industry’s 8.4% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.1%.